National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
Quit Smoking Today
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

R(+)XK469
The R-isomer of a synthetic quinoxaline phenoxypropionic acid derivative with proapoptotic and antiproliferative activities. R(+)XK469 selectively inhibits topoisomerase II-beta, blocks activation of MEK/MAPK signaling kinases, stimulates caspases, and upregulates p53-dependent proteins, including cyclins A and B1, thereby arresting cancer cells in the G2/M phase of the cell cycle. Both R(+) and S(-) isomers of this agent are cytotoxic, although the R-isomer is more potent. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:XK469
Chemical structure names:
  • 2-{4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}propionic acid
  • propanoic acid, 2-[4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy}-, (+ )-(R)-



Previous:Quinamed, quinidine, quinine, Quixin, Qvar
Next:R-(-)-gossypol acetic acid, R-CHOP regimen, R-flurbiprofen, racemic XK469, RadiaPlex Rx Gel

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov